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Abstract
Background: Due to limitations of conventional medicine for atopic eczema (AE), complementary and alternative
medicine (CAM) is widely used as an alternative, maintaining, or simultaneous treatment for AE. We aimed to
evaluate the beneficial and harmful effects of CAM for children with AE under 14 years old.
Methods: We searched for randomized trials on CAM in 12 Chinese and English databases from their inception to
May 2018. We included children (< 14 years) diagnosed with AE, who received CAM therapy alone or combined
with conventional medicine. We extracted data, and used the Cochrane “Risk of bias” tool to assess methodological
quality. Effect was presented as relative risk (RR) or mean difference (MD) with 95% confidence interval (CI) using
RevMan 5.3.
Results: Twenty-four randomized controlled trials involving 2233 children with AE were included. Methodological
quality was of unclear or high risk of bias in general. The trials tested 5 different types of CAM therapies, including
probiotics, diet, biofilm, borage oil, and swimming. Compared to placebo, probiotics showed improved effect for
the SCORAD index (MD 9.01, 95% CI 7.12–10.90; n = 5). For symptoms and signs such as itching, skin lesions, CAM
combined with usual care was more effective for symptom relief ≥95% (RR 1.47, 95% CI 1.30–1.68; n = 8), and for
≥50% symptoms improvement (RR 1.34, 1.25–1.45; n = 9) compared to usual care. There was no statistic significant
difference between CAM and usual care on ≥95% improvement or ≥ 50% improvement of symptoms. However,
swimming, diet and biofilm showed improvement of clinical symptoms compared with usual care. At follow-up of
8 weeks to 3 years, CAM alone or combined with usual care showed lower relapse rate (RR 0.38, 0.28–0.51, n = 2; RR
0.31, 0.24–0.40, n = 7; respectively) compared to usual care. Twelve out of 24 trials reported no occurrence of severe
adverse events.
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Conclusions: Low evidence demonstrates that some CAM modalities may improve symptoms of childhood AE and
reduce relapse rate. Safety remains unclear due to insufficient reporting. Further well-designed randomized trials are
needed to confirm the potential beneficial effect and to establish safety use.
Keywords: Complementary and alternative medicine, CAM, Atopic eczema, Children, Randomized controlled trials,
Systematic review, Meta-analysis, Clinical evidence
Background
Eczema, as defined by the World Allergy Organization,
encompasses both atopic and non-atopic conditions, and
is commonly referred to as atopic eczema (AE) or atopic
dermatitis (AD) [1]. AE is a chronically relapsing inflam-
matory skin disease, often found in children under the
age of 14 years. It impairs people’s quality of life [2] and
the prevalence of AE is estimated to be 15–20% in chil-
dren worldwide [3]. As one of the most common inflam-
matory skin diseases, AE has a prevalence exceeding
10% of children in some populations [4]. There is an in-
creasing number of studies focusing on AE, such as clin-
ical trials and systematic reviews [5].
AE can be caused by multiple and complex risk factors
such as irritants, contact allergens, food, inhaled aller-
gens, stress or infection [6]. The pathogenesis of eczema
is a complex interplay of numerous elements including
immune, genetic, infection and neuroendocrine factors
and their interaction with the environment [2]. More-
over, the diagnosis of AE relies on the assessment of
clinical features because there is no definitive/conclusive
test to diagnose the condition. The clinical characteris-
tics are itching, skin inflammation, a skin barrier abnor-
mality, and susceptibility to skin infection [7]. Although
not always recognized by health-care professionals as be-
ing a serious medical condition, AE can have a signifi-
cant negative impact on quality of life for children and
their parents and care takers [8]. Children with AE may
suffer from lack of sleep, irritability, daytime tiredness,
emotional stress, lowered self-esteem and psychological
disturbance [9]. Moreover, many cases of AE clear or
improve during childhood, whereas others persist into
adulthood [8]. Thus, there is a substantial need for
cure and symptom relief as early as possible.
However, despite the common claims for curative in-
terventions, there is currently no known cure for AE
in allopathic medicine [9].
Therefore, there is an increasing number of trials
studying complementary and alternative medicine
(CAM) to treat children with AE. There is a growing
interest in CAM as a primary, maintenance, or simultan-
eous treatment for AE [10]. These studies suggest that
CAM may improve health related quality of life of chil-
dren. In fact, many people rely on these treatments as
their primary approach to relieve their illness or at least
to improve the duration and quality of symptomatic re-
lief [10]. The most frequently used CAM modalities are
herbal medicine, vitamins, Ayurveda, naturopathy, hom-
eopathy, traditional healing [6], and probiotics [11].
However, current literature, published protocols and sys-
tematic reviews have not involved or included all kinds
of CAM modalities. Moreover, we were not able to find
any systematic review focusing on CAM with AE in chil-
dren (< 14 years). Therefore, we conducted a compre-
hensive literature search involving CAM for AE in
children (< 14 years) to add to current available evidence
in order to inform clinical practice further.
Methods
The protocol of the review was registered in PROSPERO
(CRD42017071267) on 7th of August 2017 (Available from:
http://www.crd.york.ac.uk/PROSPERO/). The content of
the review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [12].
Eligibility criteria
Type of studies
Randomized controlled trials (RCTs) were included in
the systematic review.
Type of participants
Children (< 14 years) diagnosed with AE by defined cri-
teria or validated instruments or tools based on either the
UK Working Party, Hanifin and Rajka (Hanifin 1980) or
explicitly stated provider based diagnostic criteria [13]
were included. Trials without clear diagnostic criteria but
with detailed description of clinical features to be diag-
nosed as AE were also eligible for inclusion in a subgroup
analysis. The limited age of < 14 years was set because of
the maximum age as younger adolescents defined by
WHO. No gender or ethnicity limitations were set.
Type of intervention
CAM modalities used alone or in combination with con-
ventional therapies for children (< 14 years) were included.
CAM terms have different concepts: If a non-mainstream
practice is used together with conventional medicine, it’s
considered as “complementary”. If a non-mainstream
practice is used in place of conventional medicine, it is
considered “alternative” [14]. Since a separate review on
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Traditional Chinese Medicine (TCM) for AE will be pre-
pared due to clinical heterogeneity, we included the fol-
lowing CAM modalities: dietary advices/restriction,
dietary supplements, probiotics, prebiotics, psychological
interventions, oral evening primrose oil or borage oil, spe-
cific allergen immunotherapy, aromatherapy, bath therapy,
bioresonance, chromotherapy, homeopathy, hypnotherapy
and relaxation techniques in addition to some other CAM
modalities that are known to be used for treating AE [10].
However, CAM is different from the new drug to esti-
mate effectiveness, but to focus on its efficacy. So, it is
sometimes difficult to to split CAM modalities up into
parts to investigate effectiveness and safety of CAM
modalities separately, except the placebo-controlled ran-
domized trials [15]. Therefore, from the component
level, CAM in the intervention group can be classified
as above specific modalities such as probiotics, bath
therapy, and so on. And from the system level, CAM
can be considered as an integrated “whole system” of
intervention.
Type of outcomes
Primary outcomes included clinical disease severity mea-
sured by one or more of the following instruments: (1)
global improvement in objective AE outcomes as mea-
sured by scoring atopic dermatitis index (SCORAD); ec-
zema area and severity index score (EASI); Nottingham
eczema severity score (NESS) reported by a clinician;
global improvement in subjective AE outcomes as mea-
sured by patient oriented eczema measure (POEM);
itching visual analogue score (VAS); dermatology life
quality index (DLQI) reported by participants or their
parents. (2) Frequency of treatment discontinuation due
to adverse effects. Secondary outcomes included (1) re-
lapse rate; (2) proportion of participants with ≥50%
symptoms and signs improvement in a given outcome as
assessed by a clinician; (3) type, frequency, and severity
of adverse events.
Search strategy
We conducted systematic literature searches in 12 elec-
tronic databases, including 4 Chinese databases (China
National Knowledge Infrastructure (CNKI), Wanfang
Database, Chinese Scientific Journal Database (VIP), and
SinoMed), and 8 English databases: PubMed, EMBASE
via OVID, AMED (Allied and Complementary Medicine
Database) via OVID, CINAHL (Cumulative Index to
Nursing and Allied Health Literature) via EBSCO, Psy-
choInfo, CAM-QUEST, the GREAT database (the Global
Resource for Eczema Trials: www.Greatdatabase.org.uk),
and the Cochrane Library from their inception date until
May 2018. The filters were English and Chinese lan-
guage (Additional file 1). We also searched in the grey
literature such as conference proceedings and
dissertations in CNKI and Wanfang for unpublished tri-
als and trial protocols. References of all included studies
were hand searched for additional eligible studies.
Study selection and data extraction
Two authors (CL Lu and SB Liang) independently exam-
ined the full text to identify the eligible trials. Four au-
thors in pair (CL Lu, XH Liu, X Wang, and X Bai)
extracted data independently from the included studies
according to a predesigned data sheet. Any disagreement
was resolved by discussion with a third author (JP Liu).
Following items were extracted: publication year, study
type, funding, inclusion/exclusion criteria, diagnostic cri-
teria, study methodology, demographic characteristics of
the participants, details of intervention and controls,
outcome measures methods, adverse events, and results.
Quality assessment
Two authors (CL Lu and XH Liu) used the risk of bias
tool [16] to assess the methodological quality of the in-
cluded trials. Seven items including random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting and other
bias such as pharmaceutical funding, were used to be
judged as “low risk”, “high risk”, or “unclear risk”. Any
disagreements were resolved by discussion with a third
author (JP Liu).
Data analysis
We used RevMan 5.3 software for data analysis. For con-
tinuous data, we used mean difference (MD) with 95%
confidence intervals (CI), and for dichotomous data we
used relative risk (RR) with 95% CI. We performed
meta-analyses for trials if the study design, participants,
interventions, control, and outcome measures were simi-
lar. Bulk data were synthesized quantitatively by descrip-
tive counting. Other data not suitable for pooling
analysis were synthesized qualitatively.
We used I-square (I2) to test the statistical heterogen-
eity as recommended by the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We
considered I2 statistic value greater than 50% as a sug-
gestion that there might be substantial heterogeneity
[16]. We used random effects model for data pooling
with significant heterogeneity (I2 ≥ 50%), otherwise a
fixed effect model was applied. If the data were available,
we did subgroup analyses for subcategories of CAM
modalities.
A sensitivity analysis was conducted to explore the in-
fluence of the type of randomized trials (parallel or
cross-over randomized) and the quality of trials (high or
low) if the data were available. A funnel plot was
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generated to explore possible publication bias if more
than ten trials were included in a meta-analysis.
Results
Description of studies
Our searches identified 4807 citations. After reviewing the
titles and abstracts, 3034 citations were excluded due to
duplication, reviews, and non RCTs. After scanning the
full texts to identify the participants who were over
14 years, we excluded 1648 publications. Among 125
publications that were eligible, three publications were ex-
cluded [17–19] due to inappropriate allocation of partici-
pants. We excluded 98 trials for the intervention of TCM
in separate systematic review. Finally, there were 24 trials
[20–43] with a total of 2233 children (< 14 years) included
in this review (Fig. 1). Eleven trials [33–43] were published
in English, and 13 trials [20–32] were in Chinese. We did
not identify any unpublished study. Twenty-two trials
[20–41] had two arms with parallel groups, one trial [42]
had three arms, and one trial [43] had five arms.
Study characteristics
The details of the 24 trials are presented in Table 1. The
sample size of these studies ranged from 15 to 298 par-
ticipants. The age ranged from 2 months to 13 years.
We defined the conventional therapy with more than
two modalities (e.g. topical and systemic anti-allergic,
and immunomodulatory therapy) as “usual care” in 24
trials [9]. Every trial had more than two modalities of
conventional therapy except placebo. Therefore, from
the component level, CAM modalities of 22 trials [21,
23–43] in the intervention group could be classified as
Fig. 1 Flow diagram of study selection and different sub-groups interventions included in this review









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lu et al. BMC Complementary and Alternative Medicine  (2018) 18:260 Page 7 of 15
probiotics, diet, biofilm, and borage oil (undershirts
coated with oil) (more in Table 2). Moreover, two trials
[20, 22] had their main modality referring to swimming
and biofilm while accompanying other modalities. So,
we considered for three different comparisons in the
two-arm trials from system level: CAM versus usual care
[20–22], CAM plus usual care versus usual care [23–32],
and CAM (probiotics) versus placebo [33–41]. For the
two trials with three or more arms [42, 43], probiotics
was compared with other formula of probiotics, placebo,
usual care, or observation with no intervention.
Risk of bias of included trials
The trials only reporting that the study was “randomized”
were defined as “unclear” risk of bias, while the trials de-
scribing a specific method of randomized sequences gen-
eration, allocation concealment, and blinding as “low” risk
of bias. Other bias accessed the funding scheme. Trials
supported by non-commercial funding were defined as
“low” risk of bias, trials funded by pharmaceutical com-
panies were classified as “high” risk of bias, no informa-
tion as “unclear” risk of bias. Eight trials [22, 24, 29, 31,
33, 34, 37, 41] reported the random allocation by random
number table or computer generated-list. Only five trials
[33, 34, 37, 38, 40, 41] reported the allocation concealment
by using computer-generated random numbers or
randomization software, which can conceal the allocation
automatically. Ten trials [33, 34, 36–43] reported double
blinding. Eight trials [33–37, 39, 41, 43] reported the drop
out in both intervention group and control group, and
only four trials [33, 39, 41, 43] used intention-to-treat
(ITT) to analyze for all outcome [33, 39, 41] and primary
outcome [43], and the other four trials [34–37] analyzed
data by per-protocol (PP) and reported the data of avail-
able participants. Besides, two trials [39, 41] analyzed by
both ITTand PP. We considered one trial [34] as high risk
of incomplete data for loss to follow up without ITT ana-
lysis because of 13 withdrawals in intervention group and
16 withdrawals in control group among the 100 partici-
pants in the trial. Four trials [33, 39, 41, 43] were consid-
ered as low risk of bias and the others as unclear. Eleven
trials [21, 25, 29, 33, 35–37, 40–43] mentioned
non-commercial funding. Three trials [33, 39, 43] reported
that probiotic manufacturers produced the drugs used.
We considered these three trials [33, 39, 43] as high risk
of bias for conflict of interest (Fig. 2). Sample size calcula-
tion was reported in five trials [33, 35, 37, 41, 43] accord-
ing to disease prevalence [33], symptoms and signs
reduction in treatment group by 30% [34, 41], 34% [37]
and in placebo group by 15% [34], 17% [37], 10% [41], and
symptoms and signs scale of SCORAD for a standard de-
viation increments of 7.65 [43]. The other trials did not re-
port any detail of sample size calculation. We considered
the other bias of power calculation as unclear.
Effects of interventions
The 24 trials tested five CAM interventions: combin-
ation of probiotics (72%, n = 18) [23–25, 27–43], biofilm
(12%, n = 3) [22, 26, 32], diet (8%, n = 2) [21, 43], swim-
ming (4%, n = 1) [20], and undershirts coated with bor-
age oil (4%, n = 1) [38] (Table 2).
Twenty-two two-arms trials [20–41] involved CAM mo-
dalities, including probiotics, swimming, diet, borage oil,
and biofilm. Three different comparisons were summa-
rized: CAM versus placebo, CAM versus usual care, and
CAM plus usual care versus usual care alone. In addition
to this, two multi-arm trials [42, 43] used different pro-
biotic formulae in different groups to compare with pla-
cebo, observation with no intervention or diet. Table 3
showed the detailed results of the effect estimation.
Global improvement (symptoms and signs improvement
≥95%, such as itching, skin lesions, swelling, and papula)
Global improvement was better for CAM (probiotics)
compared with placebo in five trials [35, 37, 39–41] in-
cluding 323 participants (MD 9.01, 7.12–10.90; I2 = 37%).
Three trials [20–22] with 566 participants showed no dif-
ference between CAM alone (swimming, diet, or biofilm)
and usual care (RR 1.43, 0.82–2.48; I2 = 91%). Eight trials
[23–27, 29, 30, 32] involving 763 participants showed bet-
ter effect from CAM plus usual care (RR 1.47, 1.30–1.68;
I2 = 11%) compared with usual care.
Apart from statistical heterogeneity, the interventions in
three trials [20–22] were totally different, including swim-
ming [20], diet [21], biofilm [22], and one trial [20] investi-
gated swimming in combination with Chinese herbal
medicine lotion and tuina (Chinese massage for children).
We conducted a qualitative description on these three
trials. One trial [20] tested swimming, Chinese herbal
medicine lotion and tuina compared to usual care. The
intervention group showed more symptom reduction than
the control group, however, not at a significant level. One
trial [21] compared fasting and rotation diet with Pevisone
paste, and reported beneficial effects of diet on symptom
improvement. Another trial [22] showed statistically sig-
nificant effects of Velvetfeeling Lotion (biofilm) on symp-
tom improvement when compared with usual care.
Relapse rate
CAM showed lower relapse rate compared to usual care
(RR 0.38, 0.28–0.51; n = 2, 418 participants) [20, 21].
CAM plus usual care showed lower relapse rate com-
pared to usual care (RR 0.31, 0.24–0.40; n = 7, 698 par-
ticipants) [24, 25, 27–31]. Nine trials [33–41] with 622
participants compared probiotics with placebo, but did
not report the relapse, and rest of two trials [22, 23] with
188 participants did not report the relapse either.
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≥50% improvement of symptoms and signs (such as itching,
skin lesions, swelling, and papula)
Three trials [20–22] with 566 participants showed no differ-
ence between CAM alone (RR 1.20, 0.90–1.60; I2 = 92%)
and usual care. Nine trials [23–27, 29–32] with 833
participants showed improvement from CAM (RR 1.34,
1.25–1.45; I2 = 35%) in addition to usual care compared
with usual care alone. Nine trials [33–41] with 622 partici-
pants compared probiotics with placebo reported as con-
tinuous data resulting in unavailable outcome for ≥50%
improvement of symptoms.
Apart from statistical heterogeneity, three trials had clin-
ical heterogeneity for different CAM modalities [20–22].
One trial [20] showed that swimming had more children
with improvement of symptoms and signs of ≥50% than
the control group, but not at a significant level. One trial
[21] showed significant effects of diet. Another trial [22]
reported the positive effect of biofilm compared with
usual care.
Adverse events
Only 12 trials (50%) [20, 22, 24, 25, 29, 30, 32, 35–37,
39, 43] reported the outcome of adverse events. Among
these, four trials [27, 29, 35, 36] reported no occurrence
of adverse events in either groups, and one trial [39] re-
ported no relation between adverse events and the tested
product without any details about adverse events, while
seven trials [20, 22, 24, 30, 32, 37, 43] reported that chil-
dren (< 14 years) with adverse events gradually adapted
to treatments without extra treatment or that the ad-
verse events was not related to the medications under
investigation (Table 4). No severe adverse event such as
death or hospitalization were reported. The reported ad-
verse events included crying, irritability, and worsening
of skin lesions (reddening) (Table 4).
Additional analysis
Since the fact that each comparison did not include
more than 10 trials, we were not able to conduct
meaningful funnel plot analysis in order to identify the
publication bias. Due to the same quality and the type of
randomized trials, we could not conduct sensitivity ana-
lysis in this aspect. Besides, significant heterogeneity in
two outcomes with two comparisons was more than 50%
(I2 ≥ 50%), so we conducted a subgroup meta-analysis or a
meaningful sensitivity analysis.
The global improvement (≥95% improvement) and ≥
50% improvement of symptoms and signs in probiotics
compared with usual care in three trials with 566 par-
ticipants [20–22] showed I2 as 91 and 92%. The inter-
ventions were very heterogeneous in the trials
including swimming [20], diet [21], and biofilm [22].
One trial [20] investigated not only swimming but also
Chinese herbal medicine lotion and tuina. We con-
ducted a sensitivity analysis, which showed improvement
from CAM both for global improvement ≥95% improve-
ment) (RR 1.77, 1.36–2.31; n = 2) and ≥ 50% improvement
of symptoms and signs (RR 1.33, 1.16–1.52; n = 2).
Discussion
Summary of findings
This review identified 24 RCTs involving 2233 children
(< 14 years) with AE. The findings suggest that some of
the CAM modalities used alone or in combination with
usual care may relieve the symptoms and signs of AE
with ≥95% and ≥ 50% improvement, such as itchiness,
skin lesions, swelling, and papula, in addition to reduce
relapse of eczema. Moreover, some CAM modalities
(such as probiotics) showed significant effect compared
with placebo. The evaluated modalities appear to be safe
and tolerated for lower relapse rate in CAM modality
group. In spite of unclear pathogenesis of AE, CAM mo-
dalities may reduce symptoms and signs, and relapse of
AE compared to conventional therapies.
The majority of trials had unclear risk of bias in many
domains such as allocation concealment, blinding, miss-
ing data, and sample size calculation. Due to the unclear
risk of bias of included trials, we could not come to firm
Fig. 2 Risk of bias graph
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conclusions from the evidence of the included trials in
this review.
Comparison with previous studies
By searching the Cochrane Library with “AE”, “AD”, and
“CAM”, there are 19 Cochrane reviews and 11 other re-
views published, and after scanning, 9 reviews [13, 44–51]
with CAM related to children (< 14 years) for treating or
preventing. These reviews or protocols included both
children and adults, and even pregnant women to pre-
vent, cure and explore the pathogenesis of AE. We
found only one protocol [44] similar to our review, but
was withdrawn as the author gave up the title “Comple-
mentary and alternative medicine treatments for AE”. In
addition, the previous studies did not exclude the aller-
gic diseases (such as asthma, and intestinal diseases) to
focus on AE. Our review included children (< 14 years)
suffering only from AE. Moreover, most reviews investi-
gated the specific treatment like probiotics, based on
pathological mechanisms but ignoring the complex and
unclear pathogenesis of AE. The findings of our review
are based on the symptom relief of AE and we included
more comprehensive trials involving CAM for children
(< 14 years).
Strengths and limitations
Although great effort was made to retrieve all trials, we
still cannot confirm that we were able to cover all the
evidence due to non identified unpublished data.
Besides, selecting and extracting data may also lead to
some bias. We included only children under the age of
14 as this is the maximum age as younger adolescents
defined by WHO, which may exclude some studies due
to unavailable data for their participants over the age of
14 years. In addition, due to the various treatment for
AE with an integrated “whole system” of care approach,
we considered the control group with usual care as the
system effect. The intervention group with CAM for a
specific modality as the component efficacy, which can-
not be used to document or disprove the effectiveness of
a “whole system” treatment approach [15]. Additionally,
in terms of the statistical heterogeneity and the variabil-
ity in the CAM modalities, we were not able to conduct
a subgroup meta-analysis, meaningful sensitivity analysis
and funnel plot analysis. These factors limit the conclu-
siveness and robustness of this systematic review.
Implications for research
In fact of the limitations of this review, future trials
should be designed as multi-center, double-blind placebo
controlled trials with sufficient power, and reported ac-
cording to the CONSORT (Consolidated Standards for
Reporting Trials) Statement [52]. In addition, trials
should record the relapse with sufficient length of
follow-up. Besides, it is important to provide the definite
safe treatments to the patients. Thus, adverse events in
each group should be reported respectively so that we
could retrospect the reason of different modalities and
be easy to estimate the safety of CAM modalities.
Conclusion
Based on evidence from this systematic review we found
some promising effect of CAM modalities on reducing
symptoms and signs, and relapse of AE. However, it is still
premature to recommend the therapy in clinical practice
due to the limited number of trials and general low meth-
odological quality of the included trials. Further rigorously
double-blind, placebo-controlled trials are warranted to
confirm efficacy of the CAM modalities for AE.
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RCTs: Randomized clinical trials; RR: Relative risk; SCORAD: Scoring atopic
dermatitis index; SMD: Standardized mean difference; VAS: Itching visual
analogue score; VIP: Chinese Scientific Journal Database
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